长春高新(000661.SZ)：子公司伏欣奇拜单抗注射液境内生产药品注册临床试验申请获得受理

Group 1 - The core point of the article is that Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the clinical trial application of Fuxin Qibai monoclonal antibody injection [1] Group 2 - The acceptance of the clinical trial application indicates a significant step forward for the company's product development in the domestic market [1] - This development may enhance the company's position in the pharmaceutical industry, particularly in the monoclonal antibody segment [1] - The news reflects the ongoing regulatory support for innovative drug development in China [1]